UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 08/2018, Volume 16, Issue 8, pp. 1063 - 1064
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 08/2018, Volume 16, Issue 8, pp. 1063 - 1064
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 375 - 384
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Male | Melanoma - pathology | CTLA-4 Antigen - immunology | Drug-Related Side Effects and Adverse Reactions - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | CTLA-4 Antigen - therapeutic use | Neoplasm Staging | Paclitaxel - administration & dosage | Medical colleges | Care and treatment | Chemotherapy | Immunotherapy | Immunoglobulin G | Melanoma | Cancer | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dacarbazine - therapeutic use | Humans | Middle Aged | Oximes - therapeutic use | Male | Treatment Outcome | Antineoplastic Agents, Alkylating - therapeutic use | Young Adult | Disease-Free Survival | Melanoma - genetics | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Imidazoles - therapeutic use | Mutation | Proto-Oncogene Proteins B-raf | Antimitotic agents | Usage | Patient outcomes | Melanoma | Research | Antineoplastic agents | Drug therapy | Meetings | Human immunodeficiency virus--HIV | Committees | Clinical trials | Acute coronary syndromes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 09/2018, Volume 392, Issue 10151, pp. 971 - 984
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Melanoma - epidemiology | Melanoma - etiology | Age Distribution | Neoplasm Metastasis - therapy | Skin Neoplasms - therapy | Humans | Risk Factors | Antineoplastic Agents - therapeutic use | Skin Neoplasms - epidemiology | Ultraviolet Rays - adverse effects | Incidence | Randomized Controlled Trials as Topic | Sunlight - adverse effects | Mass Screening | Protein Kinase Inhibitors - therapeutic use | Skin Neoplasms - mortality | Skin Neoplasms - etiology | Melanoma - therapy | Neoplasm Staging | Melanoma - mortality | Medical colleges | Mortality | Melanoma | Antibodies | Metastasis | Epidemiology | Viral antibodies | Analysis | Skin | Mitogens | Protein kinases | Germany | Medical informatics | Medical innovations | Clinical trials | Raf protein | Family medical history | Kinases | Cancer therapies | Metastases | Skin cancer | Proteins | Signal transduction | Age | Containment | Medical research | Threonine | MAP kinase | Protein kinase inhibitors | Survival | Chemotherapy | Sunburn & sun tanning | Inhibitors | Cell death | Mutation | Health risk assessment | Prolongation | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Double-Blind Method | Follow-Up Studies | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Survival Rate | Treatment Outcome | Alanine Transaminase - blood | Antineoplastic Agents - administration & dosage | Diarrhea - chemically induced | Melanoma - secondary | Hypophysitis - chemically induced | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Melanoma - drug therapy | Intention to Treat Analysis | Female | Aged | Clinical trials | Complications and side effects | Medical colleges | Care and treatment | Metastasis | Melanoma | Index Medicus | Life Sciences | Cancer
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 435 - 445
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Dacarbazine - administration & dosage | Prognosis | Follow-Up Studies | Membrane Proteins - genetics | Humans | Middle Aged | Male | Survival Rate | Melanoma - pathology | Mutation - genetics | Benzimidazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Melanoma - genetics | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Neoplasm Staging | Medical colleges | Care and treatment | Hospitals | Sarcoma | Immunotherapy | Melanoma | Skin | Research institutes | Analysis | Index Medicus
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 08/2020, Volume 18, Issue 8, pp. 928 - 929
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 05/2015, Volume 13, Issue 5, p. 485
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 716 - 728
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Neoplasm Recurrence, Local - radiotherapy | Skin Neoplasms - drug therapy | Skin Neoplasms - radiotherapy | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - surgery | Neoplasm Recurrence, Local - pathology | Neoplasm Metastasis | Pyridines - adverse effects | Aged, 80 and over | Adult | Female | Skin Neoplasms - surgery | Skin Neoplasms - pathology | Carcinoma, Basal Cell - radiotherapy | Pyridines - administration & dosage | Double-Blind Method | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Basal Cell - pathology | Disease-Free Survival | Carcinoma, Basal Cell - surgery | Biphenyl Compounds - administration & dosage | Carcinoma, Basal Cell - drug therapy | Aged | Medical colleges | Care and treatment | Basal cell carcinoma | Surgical clinics | Clinical trials | Skin | Metastasis | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 733 - 740
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Dacarbazine - adverse effects | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents, Alkylating - administration & dosage | Skin Neoplasms - enzymology | Benzimidazoles - administration & dosage | Time Factors | DNA Mutational Analysis | Brazil | Proto-Oncogene Proteins B-raf - metabolism | Dacarbazine - administration & dosage | Genetic Predisposition to Disease | Neoplasms, Unknown Primary - genetics | Europe | Logistic Models | Antineoplastic Agents, Alkylating - therapeutic use | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Mutation | Antineoplastic Agents, Alkylating - adverse effects | Melanoma - mortality | Dacarbazine - therapeutic use | United States | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Melanoma - enzymology | Neoplasms, Unknown Primary - enzymology | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | Neoplasms, Unknown Primary - drug therapy | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Neoplasms, Unknown Primary - mortality | Melanoma - secondary | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Aged | Neoplasms, Unknown Primary - pathology | Care and treatment | Chemotherapy | Gene mutations | Analysis | Melanoma | Metastasis | Cancer | Index Medicus
Journal Article